Pharmaceutical Company
Appears in 10 stories · Last updated Oct 29, 2026
Preparing to launch Hibsago in the US within about 10 days of its October 28 call; approved in the US and Japan
The Food and Drug Administration approved Hibsago on October 20 for adults with chronic hepatitis B who have no cirrhosis and have taken antiviral pills for at least six months. In two late-stage trials, 19% of patients who took it had no detectable virus 24 weeks after ending all treatment; none of the 614 placebo recipients did.
Updated Oct 29
Manufacturer of Jemperli; sponsor of the AZUR-1 trial
The FDA granted accelerated approval to Jemperli (dostarlimab) on October 19 for adults with a genetic subtype of locally advanced rectal cancer. It is the first immunotherapy cleared for these patients, and trial data show most can skip chemotherapy, radiation and surgery.
Updated Oct 23
As of October 2026: Acquirer — deal completed September 2026
GSK closed its $10.6 billion purchase of Nuvalent in September, netting out to about $9.4 billion in cash. Both lung cancer drugs central to the deal were still under FDA review at closing; a ruling on neladalkib is due November 27.
Updated Oct 8
As of September 2026: Competitor developing the ADC risvutatug rezetecan
Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.
Updated Sep 29
As of September 2026: Holds ex-China rights to Ris-Rez
Two rival antibody-drug conjugates just beat the standard of care in relapsed small-cell lung cancer. Roche-partnered Tam-Peli held median survival at 13.3 months; GSK's competitor got 18.5. Both faced the same decades-old chemotherapy — and that five-month gap is the story.
Updated Sep 14
As of September 2026: Developer of the experimental drug GSK2256294
Inflammation is supposed to stop once the threat passes. University College London researchers found the body's built-in brake for that process, and a drug can press it. In a controlled human trial, the drug sped up pain resolution and cut immune cells tied to chronic disease.
Updated Sep 13
As of September 2026: Holder of ex-China rights to HS-20093, running global phase 3 trials
On September 2, 2026, China's drug regulator accepted the first marketing application for Hansoh Pharmaceutical's HS-20093, a targeted cancer drug built around the protein B7-H3. The filing covers small cell lung cancer after prior platinum-based chemotherapy and follows a July phase 3 win: the ARTEMIS-008 trial met its primary endpoint of overall survival, making HS-20093 the first B7-H3-directed antibody-drug conjugate to show a survival benefit in any tumor type.
As of May 2026: Acquirer; expanding immunology portfolio ahead of patent cliffs
For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.
Updated May 22
As of May 2026: Actively investigating AS01 adjuvant for dementia prevention through major clinical studies
A shingles vaccine is showing up in dataset after dataset as a dementia preventer. Oxford researchers published results in Nature Medicine in July 2024, showing Shingrix (the recombinant shingles vaccine) cuts dementia risk by 17-20% compared to unvaccinated people.
Updated May 19
As of May 2026: Market leader in adult vaccines, defending shingles monopoly
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
